Formulation and Drug Delivery

Aiming for Improved Efficacy and Patient Compliance for Topical Ophthalmics

February 03, 2023

Topical eye treatments can be beneficial for patients with a growing array of eye diseases, but only if taken appropriately.

Safeguarding Biologics—Blending Engineering Ingenuity and Managerial Excellence

February 03, 2023

Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.

The Commercial Message mRNA Products Send

February 02, 2023

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

FDA Seeks to Simplify COVID-19 Vaccination Program

January 30, 2023

FDA plans to authorize a common bivalent shot that targets both the original COVID-19 strain and Omicron subvariants.

Pharmacovigilance Risk Assessment Committee Meeting Highlights

January 16, 2023

The members reviewed the measures to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.

Opening Up Opportunities in 2023

January 03, 2023

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

Inhalation Vaccine Development

January 03, 2023

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Frontrunners in the Latest Stem Cell Technology

January 02, 2023

TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.

Getting Personal for Blockbusters in 2023

January 02, 2023

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

EMA Recommends Five Medicines for Approval

December 22, 2022

In terms of extensions, the committee recommended Adcirca, Dupixent, Edistride, Enhertu, Fintepla, Forxiga, Hemlibra, Imfinzi (including two new indications), Kerendia, Spikevax and Triumeq.